Hims & Hers' Super Bowl ad for unapproved weight loss drugs faces backlash from health experts over safety concerns.

It's no secret that dating can be overwhelming in your 20s and 30s, especially when it feels like everyone around you is ...

Operator Good day, and welcome to the fourth quarter and full year 2024 Zebra Technologies earnings conference call.

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

Hims & Hers sells a compounded weight loss medication. A telehealth company that sells a compounded version of medications used for weight loss has found itself at the center of an escalating ...

The ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales, X-ray results, sugary sodas, a pie in the ...

Controversy surrounding “Sick of the System” began nearly two weeks before the big game; Hims & Hers launched it on YouTube on Jan. 28. Medical and trade organizations, from the Obesity ...

The gainer was Hims & Hers Healthcare (NYSE: HIMS). On the day, the latter company's share price rose by over 5%, while Novo Nordisk's slid by almost 3%, and Viking took a more than 7% tumble.

The GLP-1 wars are heating up. After telehealth brand Hims & Hers aired its first Super Bowl commercial Sunday night, competitor Novo Nordisk, which makes competing weight loss drugs Ozempic and ...